|Articles|June 15, 2021

People and Business News — 6/21

The latest industry news of the past month, all in one place.

People News

Sharp has appointed Robert O’Beirn as Senior Vice President and Managing Director of its global Clinical Services business.

CROMSOURCE announced the appointment of Kris O’Brien as Global Head of TalentSource Life Sciences.

The IMA Group brought on Mike Minor as Executive Vice President of Clinical Research, and Debra Nichols as Senior Vice President of Commercial Affairs.

Clinical Ink announced the hiring of Janette Morgan as Executive Vice President, General Manager, EMEA.

Worldwide Clinical Trials, Inc. announced the promotion of Dave Bowser to Chief Operating Officer, and Sara Davis to Chief Commercial Officer.

Cytel Inc. has appointed Dr. Kyle Wathen as Vice President of Scientific Strategy and Innovation.

Signant Health announced the appointments of Jason Martin as Chief Operating Officer and Jean-Jacques Charhon as Chief Financial Officer.

Javara announced that it has appointed Brenda Reese as its first Chief Commercial Officer.

hyperCORE International chooses Seneca Harrison as their Internal Chief Diversity Officer.

Syneos Health announced the appointment of David S. Wilkes, MD, to the Company’s Board of Directors.

Business News

WCG IRB announced the launch of its 2021 International Fellows Program.

Yourway announced an expansion underway at its headquarters in Allentown, Pennsylvania, making the campus to over 300,000 square feet.

Recognition

Castor announced continued rapid adoption of its decentralized clinical trial platform to power COVID-19 studies globally.

OCT Clinical is among the top 3 CROs by the number of clinical trials launched in 2020, according to the Russian Registry of Clinical Trials.

Calyx announced that Calyx RIM has supported over 100 COVID-19 vaccine authorizations.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.